Search

Your search keyword '"Selchen, Daniel"' showing total 208 results

Search Constraints

Start Over You searched for: Author "Selchen, Daniel" Remove constraint Author: "Selchen, Daniel"
208 results on '"Selchen, Daniel"'

Search Results

1. Language discordance as a marker of disparities in cerebrovascular risk and stroke outcomes: A multi-center Canadian study

4. Health Canada drug approval process: a barrier to personalized care in multiple sclerosis

6. Time Course of Early Hematoma Expansion in Acute Spot-Sign Positive Intracerebral Hemorrhage: Prespecified Analysis of the SPOTLIGHT Randomized Clinical Trial

7. Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial

8. Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: Systematic literature review of real-world evidence

9. Expert opinion on the long-term use of cladribine tablets for multiple sclerosis:Systematic literature review of real-world evidence

11. Expert Opinion on Long-Term Use of Cladribine Tablets for Multiple Sclerosis: Systematic Literature Review of Real-World Evidence

14. Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: Systematic literature review of real-world evidence

18. Cost-Effective Options Are Changing the Landscape of MS Treatment

19. Risk for Major Bleeding in Patients Receiving Ticagrelor Compared With Aspirin After Transient Ischemic Attack or Acute Ischemic Stroke in the SOCRATES Study (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes)

22. Clinical characteristics and outcomes of multiple sclerosis patients with COVID-19 in Toronto, Canada

23. Language Discordance as a Marker of Disparities in Cerebrovascular Risk and Stroke Outcomes: A Multi-Center Prospective Canadian Study

25. Rapid Assessment and Treatment of Transient Ischemic Attacks and Minor Stroke in Canadian Emergency Departments: Time for a Paradigm Shift

26. sj-pdf-2-msj-10.1177_13524585211002097 – Supplemental material for Cognitive impairment, the central vein sign, and paramagnetic rim lesions in RIS

27. sj-pdf-1-msj-10.1177_13524585211002097 – Supplemental material for Cognitive impairment, the central vein sign, and paramagnetic rim lesions in RIS

28. Atrial Fibrillation in Patients with Cryptogenic Stroke

29. Complement Inhibition in Myasthenia Gravis and Neuromyelitis Optica Spectrum Disorder

32. Clinical Characteristics and Outcomes of Multiple Sclerosis Patients with COVID-19 in Toronto, Canada (1556)

34. MSJ948212_appendix – Supplemental material for Clinical and MRI characteristics of multiple sclerosis in patients of Middle Eastern and North African ancestry residing in Ontario, Canada

41. Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial

45. Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial

46. Expert opinion on the use of cladribine tablets in clinical practice

49. Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice.

50. (IIS01) Designing Digital Information for People With Multiple Sclerosis: Providing Access to Reliable Resources.

Catalog

Books, media, physical & digital resources